Previous 10 | Next 10 |
home / stock / bioaf / bioaf news
BIOASIS TECHNOLOGIES INC . (“ Bioasis ”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“ BBB ”) and the t...
Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB 3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potentia...
BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barr...
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSXV:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrie...
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrie...
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain bar...
NEW YORK , Feb. 24, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 20th conference are now available for on-demand viewing at VirtualInvestorConferences.com. ...
GUILFORD, CONN ., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("...
Live Investor Conference & Webinar: Growth Company CEOs Present February 20th Live Investor Conference & Webinar: Growth Company CEOs Present February 20th Canada NewsWire NEW YORK, Feb. 14, 2020 Company executives will share vision and answer audience questions a...
Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and th...
News, Short Squeeze, Breakout and More Instantly...
Bioasis Technologies Inc Company Name:
BIOAF Stock Symbol:
OTCMKTS Market:
Bioasis Technologies Inc Website:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...